Skip to main content

Table 2 The safety assessment of participants

From: Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19

Code

Fever

Rush

Heart attack

Bronchospasm

Edema

Allergic signs

Other adverse event

Arrhythmia

Safety assessment grading

NK-T-01

None

None

None

None

None

None

None

None

 + 1

NK-T-02

None

None

None

None

None

None

None

 + 2b

 + 1

NK-T-03

None

None

None

None

None

None

None

 + 1b

 + 1

NK-T-04

None

None

None

None

None

None

Low dysphoria

 + 1

 + 1

NK-T-05

None

Lowa

 + 2

None

None

None

None

D

 + 1

  1. aThe patient also had a rash on the first day of hospitalization bIt has been occurred 1 and 2 days after NK cell infusion